Cargando…

Health care‐related time costs in patients with metastatic breast cancer

BACKGROUND: Burdens related to time spent receiving cancer care may be substantial for patients with incurable, life‐limiting cancers such as metastatic breast cancer (MBC). Estimates of time spent on health care are needed to inform treatment‐related decision‐making. METHODS: Estimates of time spen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rocque, Gabrielle B., Williams, Courtney P., Ingram, Stacey A., Azuero, Andres, Mennemeyer, Stephen T., Young Pierce, Jennifer, Nipp, Ryan D., Reeder‐Hayes, Katherine E., Kenzik, Kelly M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666754/ https://www.ncbi.nlm.nih.gov/pubmed/32955793 http://dx.doi.org/10.1002/cam4.3461

Ejemplares similares

Healthy lifestyle discussions between healthcare providers and older cancer survivors: Data from 12 cancer centers in the Southeastern United States
por: Halilova, Karina I., et al.
Publicado: (2019)

Prior Treatment Time Affects Survival Outcomes in Metastatic Breast Cancer
por: Rocque, Gabrielle B., et al.
Publicado: (2020)

Out‐of‐pocket costs and burden among rural breast cancer survivors
por: Pisu, Maria, et al.
Publicado: (2017)

Examining the association among fear of COVID‐19, psychological distress, and delays in cancer care
por: Caston, Nicole E., et al.
Publicado: (2021)

Patient perspectives on chemotherapy de‐escalation in breast cancer
por: Rocque, Gabrielle B., et al.
Publicado: (2021)

Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis
por: Kamran, Sophia C., et al.
Publicado: (2018)

Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma
por: Iyer, Jayasri G, et al.
Publicado: (2015)

Patterns and predictors of end‐of‐life care in older patients with pancreatic cancer
por: Nipp, Ryan D., et al.
Publicado: (2018)

Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss
por: Best, Till Dominik, et al.
Publicado: (2021)

Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer
por: Franks, Jeffrey, et al.
Publicado: (2022)

An examination of racial differences in 5‐year survival of cervical cancer among African American and white American women in the southeastern US from 1985 to 2010
por: Weragoda, Janaka, et al.
Publicado: (2016)

Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma
por: Li, Pengxiang, et al.
Publicado: (2017)

Leveraging patient‐reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience
por: Gupta, Arjun, et al.
Publicado: (2021)

Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer
por: Nipp, Ryan, et al.
Publicado: (2018)

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
por: Salans, Mia, et al.
Publicado: (2021)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)

Patient expectations of benefit from systemic treatments for metastatic prostate cancer
por: Oswald, Laura B., et al.
Publicado: (2019)

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma
por: Ogata, Dai, et al.
Publicado: (2021)

Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot
por: Lee, Anna, et al.
Publicado: (2021)

The cost of cancer: a retrospective analysis of the financial impact of cancer on young adults
por: Landwehr, Michelle S., et al.
Publicado: (2016)

Projecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030
por: Gogate, Anagha, et al.
Publicado: (2021)

Characterizing the outcomes of metastatic papillary renal cell carcinoma
por: Connor Wells, John, et al.
Publicado: (2017)

Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
por: Iyer, Jayasri G., et al.
Publicado: (2016)

Evaluating the implementation and impact of navigator-supported remote symptom monitoring and management: a protocol for a hybrid type 2 clinical trial
por: Rocque, Gabrielle B., et al.
Publicado: (2022)

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
por: Ibrahim, Nageatte, et al.
Publicado: (2016)

Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High‐intensity Aerobic and resistance exercise for Metastatic castrate‐resistant Prostate cancer
por: Kenfield, Stacey A., et al.
Publicado: (2021)

Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration
por: Freedland, Stephen J., et al.
Publicado: (2021)

Population‐based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non‐metastatic muscle‐invasive bladder cancer
por: Benidir, Tarik, et al.
Publicado: (2021)

Cost comparison by treatment arm and center‐level variations in cost and inpatient days on the phase III high‐risk B acute lymphoblastic leukemia trial AALL0232
por: DiNofia, Amanda M., et al.
Publicado: (2017)

Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy
por: Cowey, C. Lance, et al.
Publicado: (2020)

Clinical and cost outcomes following genomics‐informed treatment for advanced cancers
por: Weymann, Deirdre, et al.
Publicado: (2021)

Ethnicity and insurance status predict metastatic disease presentation in prostate, breast, and non‐small cell lung cancer
por: Aghdam, Nima, et al.
Publicado: (2020)

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract
por: Sarfaty, Michal, et al.
Publicado: (2020)

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer
por: Brezden‐Masley, Christine, et al.
Publicado: (2020)

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases
por: Parkes, Amanda, et al.
Publicado: (2018)

Increased platelet reactivity in patients with late-stage metastatic cancer
por: Cooke, Niamh M, et al.
Publicado: (2013)

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
por: Sivapiragasam, Abirami, et al.
Publicado: (2020)

Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma
por: Ma, Lucy X., et al.
Publicado: (2020)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

The role of surgery on primary site in metastatic upper urinary tract urothelial carcinoma and a nomogram for predicting the survival of patients with metastatic upper urinary tract urothelial carcinoma
por: Zhang, Xiaodi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cacu1uj5k3h55o06vjbo09c48l